Phase III Trial For Sanofi Anti-Clotting Drug Halted Due To Excess Bleeding
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis’ idraparinux demonstrated noninferiority versus vitamin K antagonists but was associated with more bleeding, according to Lancet article.
You may also be interested in...
With European Approval Imminent, J&J/Bayer File Rivaroxaban In The U.S.
Novel anticoagulant for orthopedic surgery poised to reach market before Pfizer, Bristol, Astellas and Daiichi Sankyo compounds.
With European Approval Imminent, J&J/Bayer File Rivaroxaban In The U.S.
Novel anticoagulant for orthopedic surgery poised to reach market before Pfizer, Bristol, Astellas and Daiichi Sankyo compounds.
Sanofi/GSK Arixtra Adds DVT, Pulmonary Embolism Treatment Indications
Expanded indication comes as Sanofi prepares to divest Arixtra to GlaxoSmithKline in connection with its proposed acquisition of Lovenox-maker Aventis.